Key facts

ELIQUIS^® (apixaban), $14.4 billion

OPDIVO^®(nivolumab), $10.0 billion

ORENCIA^® (abatacept), $3.7 billion

REVLIMID^® (lenalidomide), $3.0 billion

YERVOY^® (ipilimumab), $2.9 billion

POMALYST^® / Imnovid^®(pomalidomide), $2.7 billion

REBLOZYL^® (luspatercept-aamt), $2.3 billion

BREYANZI^® (lisocabtagene maraleucel), $1.4 billion

OPDUALAG^™(nivolumab and relatlimab-rmbw), $1.2 billion

CAMZYOS^® (mavacamten), $1.1 billion

ZEPOSIA^® (ozanimod), $577 million

SPRYCEL^® (dasatinib), $493 million

ABECMA^® (idecabtagene vicleucel), $427 million

ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $368 million

SOTYKTU^™(deucravacitinib), $291 million

OPDIVO QVANTIG^™ (nivolumab and hyaluronidase-nvhy), $238 million

KRAZATI^® (adagrasib) $205 million

COBENFY^™ (xanomeline & trospium chloride), $155 million

Other growth products *, $1.9 billion

Other legacy products **, $798 million

*Includes AUGTYRO™(repotrectinib), ONUREG® (azacitidine tablets), INREBIC® (fedratinib), NULOJIX® (belatacept), EMPLICITI® (elotuzumab) and royalty revenues, including royalties received from Merck on Winrevair (Winrevair is a trademark of Merck & Co., Inc., Rahway, NJ, USA).

**Includes other mature brands.